BR112016023170A2 - biomarcadores para avaliação de hiv - Google Patents

biomarcadores para avaliação de hiv

Info

Publication number
BR112016023170A2
BR112016023170A2 BR112016023170A BR112016023170A BR112016023170A2 BR 112016023170 A2 BR112016023170 A2 BR 112016023170A2 BR 112016023170 A BR112016023170 A BR 112016023170A BR 112016023170 A BR112016023170 A BR 112016023170A BR 112016023170 A2 BR112016023170 A2 BR 112016023170A2
Authority
BR
Brazil
Prior art keywords
hiv
mammalian subject
antiretroviral therapy
relates
present
Prior art date
Application number
BR112016023170A
Other languages
English (en)
Other versions
BR112016023170B1 (pt
Inventor
Guimaraes Loturco Edson
Dale Cotrim Guerreiro Da Silva Ismael
Soubie Diaz Ricoardo
Koal Therese
Original Assignee
Biocrates Life Sciences Ag
Centro De Genomas
Idcgs Clinica De Diagnosticos Medicos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocrates Life Sciences Ag, Centro De Genomas, Idcgs Clinica De Diagnosticos Medicos filed Critical Biocrates Life Sciences Ag
Priority to BR122020000253-0A priority Critical patent/BR122020000253B1/pt
Publication of BR112016023170A2 publication Critical patent/BR112016023170A2/pt
Publication of BR112016023170B1 publication Critical patent/BR112016023170B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

a presente invenção diz respeito a conjuntos de biomarcadores metabólicos para avaliar hiv. em modalidades preferidas, a presente invenção diz respeito ao uso de conjuntos de biomarcadores para procurar e/ou diagnosticar infecção de hiv, para previsão de resposta imune de um sujeito mamífero a terapia antirretroviral e/ou prognóstico da progressão da doença hiv, e para monitorar atividade da doença hiv em um sujeito mamífero. em outras modalidades, a invenção diz respeito a métodos para procurar e/ou diagnosticar infecção por hiv, para previsão de resposta imune de um sujeito mamífero à terapia antirretroviral e/ou prognóstico da progressão da doença hiv, e para monitorar a atividade da doença hiv em um sujeito mamífero, bem como a um kit adaptado para realizar os métodos. empregando os biomarcadores específicos e o método de acordo com a presente invenção se torna possível mais propriamente e confiavelmente avaliar hiv. em particular, se torna possível pesquisar e diagnosticar hiv em um paciente com alta precisão e prever cedo em avanço a resposta terapêutica do paciente à terapia antirretroviral.
BR112016023170-8A 2014-04-04 2015-03-31 Biomarcadores para avaliação de hiv BR112016023170B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020000253-0A BR122020000253B1 (pt) 2014-04-04 2015-03-31 Biomarcadores para avaliação de hiv

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14001259.2A EP2927691B1 (en) 2014-04-04 2014-04-04 Biomarkers for assessing HIV
EP14001259.2 2014-04-04
PCT/EP2015/056977 WO2015150360A1 (en) 2014-04-04 2015-03-31 Biomarkers for assessing hiv

Publications (2)

Publication Number Publication Date
BR112016023170A2 true BR112016023170A2 (pt) 2017-10-10
BR112016023170B1 BR112016023170B1 (pt) 2023-12-12

Family

ID=50488967

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112016023170-8A BR112016023170B1 (pt) 2014-04-04 2015-03-31 Biomarcadores para avaliação de hiv
BR122020000253-0A BR122020000253B1 (pt) 2014-04-04 2015-03-31 Biomarcadores para avaliação de hiv

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020000253-0A BR122020000253B1 (pt) 2014-04-04 2015-03-31 Biomarcadores para avaliação de hiv

Country Status (9)

Country Link
US (2) US10054604B2 (pt)
EP (2) EP2927691B1 (pt)
BR (2) BR112016023170B1 (pt)
CA (1) CA2944389A1 (pt)
DK (1) DK2927691T3 (pt)
ES (2) ES2644334T3 (pt)
PT (1) PT2927691T (pt)
SG (2) SG11201608244TA (pt)
WO (1) WO2015150360A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017205460A1 (en) * 2016-05-24 2017-11-30 Excision Biotherapeutics, Inc. Metabalomics and viral diagnostics suite
WO2019200947A1 (zh) * 2018-04-16 2019-10-24 中国检验检疫科学研究院 基于LC-Q-Orbitrap的食用农产品中农药化合物电子身份数据库及检测方法
WO2019200946A1 (zh) * 2018-04-16 2019-10-24 中国检验检疫科学研究院 基于GC-Q-Orbitrap的食用农产品中农药化合物电子身份数据库及检测方法
US11169128B2 (en) 2018-04-16 2021-11-09 Chinese Academy Of Inspection And Quarantine Electronic ID database and detection method for pesticide compound in edible agro-products based on LC-Q-Orbitrap
EP3623813A1 (en) * 2018-09-17 2020-03-18 Institut d'Investigació Sanitària Pere Virgili Methods for the prognosis of hiv-infected subjects

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464740A (en) * 1992-09-08 1995-11-07 Amur Research Corp. Diagnositc agent and methods for identifying HIV infected individuals and monitoring their therapy
EP2284540A1 (en) * 2009-07-31 2011-02-16 BIOCRATES Life Sciences AG Method of diagnosing organ failure

Also Published As

Publication number Publication date
EP3126841B1 (en) 2019-07-03
PT2927691T (pt) 2017-10-27
US20170184619A1 (en) 2017-06-29
BR122020000253B1 (pt) 2023-12-19
US10725056B2 (en) 2020-07-28
US20170160246A1 (en) 2017-06-08
CA2944389A1 (en) 2015-10-08
BR112016023170B1 (pt) 2023-12-12
US10054604B2 (en) 2018-08-21
SG10201800570RA (en) 2018-03-28
DK2927691T3 (en) 2017-10-30
EP2927691A1 (en) 2015-10-07
ES2644334T3 (es) 2017-11-28
EP3126841A1 (en) 2017-02-08
EP3126841B8 (en) 2019-09-11
WO2015150360A1 (en) 2015-10-08
EP2927691B1 (en) 2017-07-19
SG11201608244TA (en) 2016-10-28
ES2749048T3 (es) 2020-03-18

Similar Documents

Publication Publication Date Title
BR112016023170A2 (pt) biomarcadores para avaliação de hiv
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
WO2016094330A3 (en) Methods and machine learning systems for predicting the liklihood or risk of having cancer
BR112013006764A2 (pt) método para avaliar um paciente, kit, meio legível por computador, método para avaliar um tratamento, método para avaliar o risco de um paciente, método para monitorar, método de diagnosticar, sistema de teste, método para classificar ou agrupar uma população de indivíduos, método para avaliar um desfecho substituto, método para tratar, uso de pelo menos um biomarcador, uso de um agente
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BR112019024701A2 (pt) métodos para auxiliar na determinação se um exame de imagem deve ser realizado em um indivíduo humano que sofreu ou pode ter sofrido uma lesão na cabeça com o uso de biomarcadores precoces
WO2014201516A3 (en) Biomarker identification
WO2015006489A8 (en) Blood-based screen for detecting neurological diseases in primary care settings
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
WO2014020502A3 (en) Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2)
GB2467704A (en) Methods of monitoring conditions by sequence analysis
BR112015008042A2 (pt) diagnósticos complementares para terapia com inibidor de quinase da família tec
AR103935A1 (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2
BR112015006284A2 (pt) cpmf como um biomarcador para diabetes e métodos associados
IN2014DN08537A (pt)
MX2018001697A (es) Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores.
BR112018073214A2 (pt) métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador
Panciani et al. Computerized gait analysis with inertial sensor in the management of idiopathic normal pressure hydrocephalus.
MX2019002918A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
Wolfe Fibromyalgia research criteria
Uysal et al. Increased serum levels of some inflammatory markers in patients with multiple sclerosis.
Le Heron et al. Wireless accelerometry is feasible in acute monitoring of upper limb motor recovery after ischemic stroke
WO2015010042A3 (en) Method of determination of risk of 2 hour blood glucose equal to or greater than 140 mg/di
Ansheles et al. New approaches to quantifying early disorders and perfusion inhomogeneity of the myocardium according to the data of single-photon emission computed tomography
PL407244A1 (pl) Bioczujnik elektrochemiczny do wykrywania białka S100B

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/03/2015, OBSERVADAS AS CONDICOES LEGAIS